Evecxia, Inc., a privately funded, clinical stage biopharmaceutical company, has expanded its previous license agreement with Duke University to include exclusive, world-wide rights to develop and commercialize methods of improving the bioavailability of 5-hydroxytryptophan (5-HTP). The original license agreement, executed in December 2015, covers issued patents and pending patent applications for slow-release 5-HTP in combination…